Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
65 participants
INTERVENTIONAL
2021-09-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research intends to answer these questions:
Does participation in the SAFE program increase perceived safety and well-being in the workplace for people with Autism Spectrum Disorder (ASD) and/or Intellectual or Developmental Disabilities (IDD)? Does participation in the SAFE program increase knowledge of actionable behaviors to prevent transmission of airborne diseases (i.e. COVID-19) in the workplace for people with IDD? When implemented through peer support, does the SAFE program have a larger increase in perceived well-being and knowledge of actionable behaviors to prevent transmission of airborne diseases (i.e. COVID-19) than when implemented through staff training and supports?
The research further intends to:
Develop health communication messages related to safe interactions and the prevention of COVID-19 and other infectious airborne diseases for autistic adults
Refine and expand the SAFE program based on stakeholder priorities and input
Evaluate the SAFE program training with Autistic adults Procedures.
The researchers will leverage current relationships with community organizations to recruit 100 participants with ASD and or IDD who are employed 10 hours or more a week and receiving employment services or supports. Organizational administrators will provide information on the study to individuals that meet the inclusion criteria. Interested individuals will contact the project research coordinator to determine inclusion. Eligible participants will be randomized into one of the 3 arms of the study, Control, Peer Interventionist Led, Staff Led.
If the participant is assigned to the staff intervention support staff will be contacted with an email or phone call. Staff members will be required to complete human subjects training. Researchers will obtain informed consent for all participants. During the first contact made with participants, written information will be provided remotely using Zoom/FaceTime or in person to all participants explaining the following in simple terms: 1) the criteria for participation, 2) the purpose of the research and the procedures involved, 3) the subject's right to withdraw at any time without penalty of any sort, 4) potential benefits to the subject, 5) potential risks, 6) assurance of anonymity, and 7) terms of remuneration. All research staff will complete training about the informed consent process prior to consenting subjects. The information described above will be reviewed and any questions answered. Participants will be obtained signed or a printed signature box used for signature when electronic signatures are unable to be obtained for consent either in person or virtually.
The researchers will collect data from young adults or transitional aged-youth with ASD or IDD to determine the efficacy and feasibility of the intervention. Recruitment occurs through the sites identified in the participant recruitment section of this proposal. Participants interested in the study will contact the primary investigator or research staff who will schedule an initial physical or virtual meeting at a place and time convenient for the participant to determine inclusion and obtain consent/assent. Participants are randomly assigned to either peer-support intervention, staff intervention or a control group. The researchers will randomize in blocks of 12 (4 to each group) until the investigators reach the targeted number of 120 or 40 participants in each group. Pre-test and post-test measures will be administered by researcher staff prior to the start of the intervention (Pre-test) and at the end of the intervention 4 weeks (Post-test ). Key stakeholders, including the participants and interventionists (occupational therapists and peer mediators), will complete qualitative interviews at the end of the intervention period for each participant. The information gathered will determine acceptability and feasibility of intervention. Participants will be asked to discuss their experiences during the intervention specific to their assigned intervention group.
A member from the research team will then contact interested individuals to set up a convenient meeting time and place for the SAFE program training. These meetings will occur remotely or in a private location convenient to the participant. The SAFE program course training will occur in small group settings or individually. The course trainings will occur 2-3 times per week for between 45-60 minutes. An appropriate curriculum has been developed by Temple University Researchers and Occupational therapy students based on many qualitative interviews, research of proper education methods, and COVID-19 practices. The curriculum is based on a series of classes designed to create an understanding of best practices and behaviors to prevent the spread of COVID-19 in the workplace. The curriculum will be adapted to meet the needs of this project and study population. The course will provides instruction in the following areas: 1) COVID-19 and how it spreads 2) Personal Protective Equipment (PPE) and How to use it properly 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy.
Participants will complete the SAFE program sessions remotely or in person in a private, quiet and convenient setting.. Participants will be randomized into two treatment arms and a control group. The first treatment arm will receive the SAFE program implemented through a staff training model. The second group will receive the program using a peer support model. The control group will continue to receive their standard vocational rehabilitation supports.
Training of the SAFE program will occur remotely or in person by staff who are trained within our research team or will be implement it in collaboration with staff or a peer specialist remotely as part of their current services. If it is in person it will be implemented at their vocational rehabilitation centers or places of employment. Research staff will be available to support the process after the training is complete.
The researchers will use a questionnaire to assess knowledge of actionable behaviors to prevent COVID-19, which reflect the core components of the SAFE program (social distancing, proper use of PPE, personal hygiene practices, and self-advocacy in the workplace). The researchers will also administer measures to determine the degree of self-advocacy and self-efficacy in the work place reported by staff and self-reported by participants. The researchers will determine how well a participant follows workplace procedures. Data will be collected either in person or virtually both at pre-test and post-test for all outcome measures. Finally, the investigators will assess perceived anxiety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
No interventions assigned to this group
Peer Intervention
Receives curriculum taught by Peer Interventionist
SAFE Employment Training
The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
Staff Delivered
Receives curriculum taught by staff
SAFE Employment Training
The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SAFE Employment Training
The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Disability, Independent Living, and Rehabilitation Research
FED
Temple University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
JEVS
Collingswood, New Jersey, United States
Community Integrated Services
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
27789
Identifier Type: -
Identifier Source: org_study_id